Clinical trials
Chronic Leukemia clinical trials
Below are recruiting chronic leukemia clinical trials, each written for real people, not researchers. We’re tracking 306 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Birmingham, AlabamaAges 18 years+ - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+ - NCT06812715RecruitingPhase 2
Pirtobrutinib after zanubrutinib for chronic lymphocytic leukemia
This trial tests a new drug, pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) who have already been treated with zanubrutinib (a similar BTK inhibitor). The goal is to see if switching to pirtobrutinib can help control the disease.
Melbourne, VictoriaAges 18 years+ - NCT06646978Enrolling by invitation
Long-term cancer risk in CML treatment trial
This study follows people who took part in the French SPIRIT trial for chronic myeloid leukemia (CML) to see if they develop other cancers later in life. It helps doctors understand the long-term safety of imatinib-based treatments.
PoitiersAges 18 years+ - NCT04935684RecruitingPhase 2
Fecal transplant after bone marrow transplant to improve gut health
This Phase 2 study tests whether a fecal microbiota transplant (a processed transplant of gut bacteria) after an allogeneic bone marrow transplant is safe and helpful. Participants may benefit by improving recovery in the gut microbiome during the post-transplant period.
AmiensAges 18 years+ - NCT06792994Recruiting
CLL treatment sequence study for patients in GCLLSG trials
This observational study looks at the order of treatments given to people with chronic lymphocytic leukemia (CLL) who took part in certain first-line studies run by the German CLL Study Group. It aims to learn how different treatment sequences affect overall survival over time.
CologneAges 18–99 - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT06788639Recruiting
Long-term study of Breyanzi for CLL/SLL in real-world care
This study looks at people with CLL or SLL who have already been treated with the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) in routine medical care. It collects information about how well the treatment works and how patients are doing over time, without giving any new treatment.
Milwaukee, WisconsinAges 18 years+ - NCT01804686RecruitingPhase 3
Long-term ibrutinib follow-up with or without nivolumab
This study looks at how safe and effective ibrutinib is over the long term, either alone or together with nivolumab. You may join if you are already in an earlier ibrutinib study and your care team feels staying on ibrutinib is worth the risk.
Duarte, CaliforniaAges 18 years+ - NCT00923507Recruiting
Study of blood cancers’ natural course and next treatment needs
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
Bethesda, MarylandAges 18–110 - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT07342478RecruitingPhase 3
Comparing two BTK inhibitors for CLL/SLL after prior treatment
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
Skokie, IllinoisAges 18 years+ - NCT07751783Recruiting
Exercise program for cancer survivors
This trial helps people who have finished cancer treatment start a supervised exercise routine to improve their health. It tests whether a structured program with professional guidance is safe and helpful.
Kaohsiung, TaiwanAges 18–80 - NCT05006716RecruitingPhase 1/Phase 2
Testing a new drug for certain B-cell blood cancers
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
Birmingham, AlabamaAges 18 years+ - NCT05869279RecruitingPhase 1/Phase 2
Study of donor immune cells for B-cell blood cancers
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Bergamo, BGAges 1 year+ - NCT06849713RecruitingPhase 2
New combination treatments for CLL or SLL
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
Boston, MassachusettsAges 18 years+ - NCT07221500RecruitingPhase 2
Study of NX-5948 for advanced CLL or SLL
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
Duarte, CaliforniaAges 18 years+ - NCT06708897RecruitingPhase 1
Study of lonitoclax for returning B-cell blood cancers
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Louisville, KentuckyAges 18 years+ - NCT06863402RecruitingPhase 2
Study of two drugs for Richter transformation lymphoma
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
Buffalo, New YorkAges 18 years+ - NCT07288515Recruiting
Acalabrutinib for CLL in routine care
This study follows people with CLL who are starting acalabrutinib (a targeted pill) for the first time, either as their first treatment or after previous therapies. The goal is to see how well it works in everyday medical practice.
GrodnoAges 18 years+ - NCT03711110Recruiting
Heart-protection plan for older people with certain cancers
This trial looks at strategies to help prevent heart and blood-vessel problems in people over 65 who have certain cancers. It may help by monitoring and treating heart risks early to lower the chance of future cardiovascular events.
Santiago de Compostela, A CoruñaAges 65 years+ - NCT03801434RecruitingPhase 2
Ruxolitinib for people with certain eosinophil overgrowth diseases
This trial studies ruxolitinib to treat illnesses where the body makes too many eosinophils (a type of white blood cell) and symptoms or organ damage happen. It may help shrink disease activity when steroids are not enough, cannot be tolerated, or the illness comes back.
Palo Alto, CaliforniaAges 18 years+ - NCT03980002RecruitingPhase 2
New treatment for CLL using alternating two drug types
This trial studies an approach for people with newly diagnosed CLL/SLL (chronic lymphocytic leukemia or related disease) who need treatment. It tests whether alternating two types of chemotherapy with ibrutinib (a targeted pill) can control the disease better and safely.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT04186520RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell lymphomas
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
Milwaukee, WisconsinAges 18–80
Hear when a new Chronic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic leukemia?
- Yes. Clin2 currently lists 306 recruiting chronic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.